ACK1 KINASE INHIBITION TO TREAT TRIPLE NEGATIVE BREAST CANCER
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Feb 13, 2014
app pub date -
Aug 12, 2013
filing date -
Aug 13, 2012
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
Compositions and methods are disclosed for treating Triple Negative Breast Cancers (TNBCs). The methods involve administering to a subject with TNBC a composition containing an Ack1 kinase inhibitor. In some embodiments, the method involves first assaying a sample from the subject for Tyr176-phosphorylated-AKT and/or Tyr284-phosphorylated-Ack1. In these embodiments, detection of the phosphorylated AKT and/or Ack1 is an indication that the subject is a suitable candidate for treatment with the Ack1 kinase inhibitor.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully